Expertise in
17
conditions

Dr. Angus A. Wilfong

Neurology | Pediatrics | Pediatric Neurology
1919 E Thomas Rd, Ambulatory Bldg 3rd Fl, 
Phoenix, AZ 
Accepting New Patients
Referral may be required
Before you request
Expertise in
17
conditions
1919 E Thomas Rd, Ambulatory Bldg 3rd Fl, 
Phoenix, AZ 

Overview

Angus Wilfong is a Neurologist and a Pediatrics provider practicing medicine in Phoenix, Arizona.

Dr. Wilfong is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Hypothalamic Hamartomas, Status Epilepticus, Epilepsy, and Seizures.

Dr. Wilfong is board certified in Psychiatry & Neurology CSQ In Child Neurology, Psychiatry & Neurology (Sub: Epilepsy), and Psychiatry & Neurology (Sub: Clinical Neurophysiolog. He is actively involved in clinical research, co-authoring 59 peer reviewed articles and participating in 5 clinical trials. Dr. Wilfong is currently accepting new patients.

Specialties

Neurology
Pediatrics
Pediatric Neurology

Licenses

Pediatrics in TX

Board Certifications

Psychiatry & Neurology CSQ In Child Neurology
Psychiatry & Neurology (Sub: Epilepsy)
Psychiatry & Neurology (Sub: Clinical Neurophysiolog

Fellowships

Baylor College of Medicine

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MercyCare
  • EPO
  • HMO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

PCH Neurology
1919 E Thomas Rd, Ambulatory Bldg 3rd Fl, Phoenix, AZ 85016

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
Enrollment Status: Completed
Publish Date: September 04, 2026
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Phase I, Open-Label, Pharmacokinetic, Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
A Phase I, Open-Label, Pharmacokinetic, Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
Enrollment Status: Completed
Publish Date: March 31, 2026
Intervention Type: Drug
Study Drug: Xcopri
Study Phase: Phase 1
The Brain Vascular Malformations Clinical Research Network: Predictors of Clinical Course, Project 2: Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome
The Brain Vascular Malformations Clinical Research Network: Predictors of Clinical Course, Project 2: Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: March 02, 2026
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
View 4 Less Clinical Trials

59 Total Publications

International Consensus on the Evaluation and Management of Hypothalamic Hamartomas: Results From a Modified Delphi Survey.
International Consensus on the Evaluation and Management of Hypothalamic Hamartomas: Results From a Modified Delphi Survey.
Journal: Neurology
Published: March 12, 2026
Similar Doctors
Expertise in
9
conditions
Dr. Kevin E. Chapman
Pediatric Neurology | Pediatrics
Expertise in
9
conditions
Dr. Kevin E. Chapman
Pediatric Neurology | Pediatrics
Referral may be required
Before you request

PCH Neurology

1919 E Thomas Rd, Ambulatory Bldg 3rd Fl, 
Phoenix, AZ 
 (0.1 miles away)
602-933-0970
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kevin Chapman is a Pediatric Neurologist and a Pediatrics provider practicing medicine in Phoenix, Arizona. Dr. Chapman is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Status Epilepticus, Seizures, Epilepsy, and Epilepsy in Children. Dr. Chapman is board certified in Psychiatry & Neurology (Sub: Child And Adolescent Ps, Psychiatry & Neurology (Sub: Epilepsy), and Psychiatry & Neurology (Sub: Clinical Neurophysiolog. Dr. Chapman is currently accepting new patients.

Expertise in
8
conditions
Dr. John F. Kerrigan
Pediatric Neurology | Neurology | Psychiatry
Expertise in
8
conditions
Dr. John F. Kerrigan
Pediatric Neurology | Neurology | Psychiatry
Referral may be required

PCH Neurology

1919 E Thomas Rd, Ambulatory Bldg 3rd Fl, 
Phoenix, AZ 
 (0.1 miles away)
602-933-0970
Languages Spoken:
English
See accepted insurances

Areas of expertise: Medical Treatment of Epilepsy, Evaluation for Epilepsy Surgery, Video-EEG Epilepsy Monitoring, Management of Hypothalamic Hamartomas. Dr. Kerrigan is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Hypothalamic Hamartomas, Epilepsy, Seizures, and Generalized Tonic-Clonic Seizure. Dr. Kerrigan is board certified in Pediatrics, Psychiatry & Neurology CSQ In Child Neurology, Psychiatry & Neurology (Sub: Epilepsy), and Psychiatry & Neurology (Sub: Clinical Neurophysiolog.

Expertise in
29
conditions
Expertise in
29
conditions
Referral required
Before you request

Barrow MAMDC And Barrow Cognitive

240 W Thomas Rd, Ste 301, 
Phoenix, AZ 
 (2.2 miles away)
602-406-6262
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marwan Sabbagh is a Neurologist practicing medicine in Phoenix, Arizona. Dr. Sabbagh is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Dementia, Lewy Body Dementia (LBD), Movement Disorders, and Deep Brain Stimulation. Dr. Sabbagh is board certified in Psychiatry & Neurology (Neurology). Dr. Sabbagh is currently accepting new patients.

Frequently Asked Questions about Dr. Angus A. Wilfong

How do I make an appointment with Dr. Angus A. Wilfong?

You can book an appointment with Dr. Angus A. Wilfong by calling their office at 602-933-0970. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Angus A. Wilfong a top-rated expert for Hypothalamic Hamartomas?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Angus A. Wilfong is classified as an Elite expert for Hypothalamic Hamartomas, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Angus A. Wilfong specialize in?

While Dr. Angus A. Wilfong is a Neurology, they have specific expertise in Hypothalamic Hamartomas, Status Epilepticus, and Epilepsy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Angus A. Wilfong participate in research or clinical trials?

Yes. Dr. Angus A. Wilfong has published 59 articles and abstracts on conditions like Hypothalamic Hamartomas. You can view a list of Dr. Angus A. Wilfong's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Angus A. Wilfong accept my insurance?

Dr. Angus A. Wilfong accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 602-933-0970 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wilfong's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 111 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile